NCT Number: NCT00126282
A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder
This study examines the efficacy of the medication D-Cycloserine in the reduction of obsessions and compulsions in individuals with obsessive-compulsive disorder (OCD). All study participants will receive Exposure and Response Prevention, a common form of behavior therapy for individuals with OCD. Half (50%) of the participants will be randomly assigned to the placebo condition and the other half (50%) will be randomly assigned to receive D-Cycloserine. Because all participants will receive 10 sessions of behavior therapy, all participants are expected to improve from this treatment.
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Anxiety Disorders Center, The Institute of Living, Hartford, Connecticut, United States
About this study
The study consists of Behavior Therapy (Exposure and Response Prevention; ERP) for OCD. Specifically, it involves exposure to anxiety-provoking situations and response-prevention of any rituals. ERP has shown to be effective for many individuals with OCD.
All assessments and treatment sessions are at no cost to the patients. 50% of the patients will randomly be assigned to the D-Cycloserine (DCS) condition, and 50% of the patients will be assigned to a placebo condition. D-Cycloserine is FDA-approved for the treatment of Tuberculosis. However, recent research in other anxiety disorders has shown that D-Cycloserine plus Behavior Therapy is more effective than Behavior Therapy alone.
This treatment study has two active conditions. That is, all patients will receive Behavior Therapy and we do expect that everybody will improve from this treatment. However, it may be that those patients in the DCS condition will improve somewhat more than those in the placebo condition.
The treatment will be structured with homework and repeated assessments every 4 weeks. Assessments are extremely important as they guide the treatment and provide the study investigators necessary information about the treatment. The treatment consists of 10 sessions (twice a week) plus post-treatment and follow-up assessments at 1 and 6 months.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Meets diagnosis for obsessive-compulsive disorder
Exclusion criteria
- History of psychotic disorders
- History of neurological disorders
- History of bipolar disorders
Treatment and study plan
D-cycloserine
DrugPrimary outcomes
-
significant reduction of OCD symptoms after the completion of treatment
Secondary outcomes
-
significant reduction of depressive symptoms after the completion of treatment
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Massachusetts General Hospital
Other
Registry information
Official study title
A Randomized, Double-blind, Placebo-controlled Medication Trial With D-Cycloserine for Individuals With Obsessive-compulsive Disorder Currently Receiving Behavior Therapy
Important dates
- Study start
- 2003
- Study completion
- 2007
- First posted
- Aug 3, 2005
- Registry last updated
- Jul 29, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
NCT06299319
Anxiety Disorders, Mental Disorders
Toronto, Ontario, Canada
View Trial DetailsA Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
NCT05624528
Anxiety Disorders, Mental Disorders
Chicago, Illinois, United States
View Trial DetailstDCS for Treatment Resistant Obsessive Compulsive Disorder
NCT03304600
Anxiety Disorders, Mental Disorders
Lyon, France
View Trial DetailsTranscranial Direct Current Stimulation Potentiation of Fear Extinction in OCD
NCT05521074
Anxiety Disorders, Mental Disorders
Boston, Massachusetts, United States
View Trial Details